Sickle cell disease is characterized by chronic hemolytic anemia and blood rheological alterations. In addition, blood coagulation abnormalities have been reported in patients with sickle cell disease and hemolysis-derived products could be involved. The investigators hypothesized that patients with sickle cell disease and severe hemolysis (Lactate Dehydrogenase level \> 484 IU/L) could have an increased risk of hypercoagulable state and subsequent thromboembolic complications.
Aged 8 years or older
Under clinical follow-up for a diagnosis of sickle cell disease, specifically genotypes S/S, S/beta0, or S/C
Patient covered by a social security or equivalent health insurance plan
Collection of the non-opposition for adults
Patient who has undergone a transfusion or therapeutic phlebotomy within the 3 months prior to inclusion
Patient participating in another interventional research protocol that may interfere with the present protocol (at the investigator's discretion)
Patient under guardianship, curatorship, or legal protection
Patient subject to a legal protection measure
Patients with sickle cell disease, followed regularly by the Sickle Cell Center of Lyon Hospitals (Hospices Civils de Lyon).
Cohort
Other
blood sampling
Other intervention3 additional citrate tubes (2.7mL)
Overall coagulation activity
To compare the overall coagulation activity (measurement of in vitro clot formation by rotary thromboelastometry (ROTEM)) between sickle cell patients with a severe haemolytic phenotype and those with a less severe haemolytic phenotype.
Click on the lead sponsor to view all of their trials.
Hospices Civils de Lyon
Lead sponsor
Laboratoire Interuniversitaire de Biologie de la Motricité (UCBL1) UR7424
Collaborator
This trial is not recruiting at the moment. You can still explore other options:
